NASDAQ:NTGN - Neon Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.55 -0.57 (-8.01 %) (As of 11/12/2018 04:00 PM ET)Previous Close$7.12Today's Range$6.19 - $7.1552-Week Range$5.62 - $16.23Volume99,525 shsAverage Volume134,571 shsMarket Capitalization$201.52 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. Neon Therapeutics, Inc. has a clinical trial collaboration with Natera, Inc. to assess the treatment response to personal cancer vaccine. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive NTGN News and Ratings via Email Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTGN Previous Symbol CUSIPN/A Webwww.neontherapeutics.com Phone617-337-4701 Debt Debt-to-Equity RatioN/A Current Ratio15.35 Quick Ratio15.35 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees84 Outstanding Shares28,300,000Market Cap$201.52 million OptionableNot Optionable Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions What is Neon Therapeutics' stock symbol? Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN." How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) issued its quarterly earnings results on Monday, August, 6th. The company reported ($7.84) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.80) by $7.04. View Neon Therapeutics' Earnings History. When is Neon Therapeutics' next earnings date? Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 12th 2018. View Earnings Estimates for Neon Therapeutics. What price target have analysts set for NTGN? 4 Wall Street analysts have issued 1 year price targets for Neon Therapeutics' shares. Their predictions range from $18.00 to $23.00. On average, they anticipate Neon Therapeutics' share price to reach $20.20 in the next twelve months. This suggests a possible upside of 208.4% from the stock's current price. View Analyst Price Targets for Neon Therapeutics. What is the consensus analysts' recommendation for Neon Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neon Therapeutics. Has Neon Therapeutics been receiving favorable news coverage? Media stories about NTGN stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neon Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Neon Therapeutics' key competitors? Some companies that are related to Neon Therapeutics include Heska (HSKA), BAVARIAN NORDIC/S (BVNRY), Mesoblast (MESO), Vericel (VCEL), Novavax (NVAX), Avrobio (AVRO), Coherus Biosciences (CHRS), Gritstone Oncology (GRTS), Scholar Rock (SRRK), Adaptimmune Therapeutics (ADAP), NanoString Technologies (NSTG), Replimune Group (REPL), PDL BioPharma (PDLI), Voyager Therapeutics (VYGR) and La Jolla Pharmaceutical (LJPC). Who are Neon Therapeutics' key executives? Neon Therapeutics' management team includes the folowing people: Mr. Hugh O'Dowd, Pres, CEO & Director (Age 53)Dr. Edward Fritsch Ph.D., Founder and Chief Technology OfficerDr. James P. Allison, FounderDr. Nir Hacohen, FounderDr. Eric S. Lander, Founder & Director (Age 61) When did Neon Therapeutics IPO? (NTGN) raised $101 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager. When does Neon Therapeutics' lock-up period expire? Neon Therapeutics' lock-up period expires on Monday, December 24th. Neon Therapeutics had issued 6,250,000 shares in its public offering on June 27th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. Who are Neon Therapeutics' major shareholders? Neon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (7.27%), BlackRock Inc. (0.97%) and Bank of New York Mellon Corp (0.06%). View Institutional Ownership Trends for Neon Therapeutics. Which major investors are selling Neon Therapeutics stock? NTGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Neon Therapeutics. Which major investors are buying Neon Therapeutics stock? NTGN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Neon Therapeutics. How do I buy shares of Neon Therapeutics? Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neon Therapeutics' stock price today? One share of NTGN stock can currently be purchased for approximately $6.55. How big of a company is Neon Therapeutics? Neon Therapeutics has a market capitalization of $201.52 million. Neon Therapeutics employs 84 workers across the globe. What is Neon Therapeutics' official website? The official website for Neon Therapeutics is http://www.neontherapeutics.com. How can I contact Neon Therapeutics? Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected] MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 32 (Vote Outperform)Underperform Votes: 39 (Vote Underperform)Total Votes: 71MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/12/2018 by MarketBeat.com StaffFeatured Article: How is a Moving Average Calculated?